STOCKHOLM, March 14, 2022 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing agreement
/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its licensing.
Expansion of Everest Medicine's licence agreement to include South Korea - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ "The accelerated approval of TARPEYO was for the indication of reduction of proteinuria, which was the endpoint of Part A of the trial, in.
Calliditas became the first Company to receive accelerated approval in IgA Nephropathy. STOCKHOLM, Feb. 24, 2022 /PRNewswire/ "The accelerated approval of TARPEYO was for the indication